Grail's Galleri blood test detected seven times more cancers than standard methods in a large study, with over half being early-stage and in hard-to-screen areas, showing promising accuracy and potential for routine screening pending FDA approval.
Recent studies presented at ASCO show that immunotherapy drugs like Opdivo, Imfinzi, and Tecentriq are effective in treating early and mid-stage cancers, significantly reducing recurrence rates and potentially transforming standard care practices for cancers such as head and neck, gastric, and colon cancers, with promising implications for patient survival and cure rates.
US researchers have developed a new DNA test that can analyze proteins in the blood to detect 18 different types of early-stage cancers across major human organs with high accuracy. This multi-screening test has the potential to reshape cancer screening guidelines and become a standard part of routine check-ups, potentially leading to improved treatment and higher survival rates. The test, developed by the US biotech firm Novelna, outperforms previous methods and could help diagnose pre-cancerous and early-stage cancer before significant damage occurs, although further studies are needed to establish its effectiveness.